Facet Biotech and Bristol-Meyers Squibb report good results for Phase I/II study with their multiple myeloma drug elotuzumab as reported on MSN.
AstraZeneca (AZ) and Rigel Pharmaceuticals strike $1.24 billion pact for the Phase II rheumatoid arthritis drug fostamatinib (aka R788). See FierceBiotech for full story.
Also reported on FierceBiotech, Thallion Pharmaceuticals and LFB Technologies sign $130 M licensing deal for treatment of Shiga-toxin producing E. coli.
Posted by Bruce Lehr Feb 16, 2010